866-997-4948(US-Canada Toll Free)

Iron Deficiency Anemia - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Pharmaceutical

No. of Pages : 60 Pages


Global Markets Directs, Iron Deficiency Anemia Pipeline Review, H1 2015, provides an overview of the Iron Deficiency Anemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5
Iron Deficiency Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Iron Deficiency Anemia Overview 7
Pipeline Products for Iron Deficiency Anemia Comparative Analysis 8
Iron Deficiency Anemia Therapeutics under Development by Companies 9
Iron Deficiency Anemia Therapeutics under Investigation by Universities/Institutes 10
Iron Deficiency Anemia Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Iron Deficiency Anemia Products under Development by Companies 14
Iron Deficiency Anemia Products under Investigation by Universities/Institutes 15
Iron Deficiency Anemia Companies Involved in Therapeutics Development 16
Panion & Bf Biotech Inc 16
Rockwell Medical, Inc. 17
Vifor Pharma AG 18
Iron Deficiency Anemia Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
ferric carboxymaltose - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ferric citrate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ferric pyrophosphate citrate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NSC-8679 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Proteins to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ST-10 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VIT-91 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Iron Deficiency Anemia Recent Pipeline Updates 35
Iron Deficiency Anemia Dormant Projects 49
Iron Deficiency Anemia Product Development Milestones 50
Featured News & Press Releases 50
Dec 15, 2014: American Regent's Injectafer (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services 50
Dec 08, 2014: American Regent Announces Clinical Data Presentations at ASH 2014 51
Nov 11, 2014: Three clinical Presentations Highlight Novel Iron Replacement Drug Triferic at ASN 53
Oct 09, 2014: Rockwell Medical Announces FDA Advisory Committee Review of Triferic For The Treatment Of Iron Replacement And Maintenance Of Hemoglobin In Hemodialysis Patients 54
Sep 01, 2014: CONFIRM-HF study demonstrates that Ferinject improves exercise capacity in patients with chronic heart failure 54
Jul 15, 2014: American Regents Injectafer (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States 55
Jun 09, 2014: Rockwell Medical Wins Appeal for Determination as Small Business for New Drug Application Filing for Triferic 56
Jun 02, 2014: Faster, more affordable treatment for Iron Deficiency Anaemia now available in Australia 57
May 28, 2014: Rockwell Medical Announces FDA Acceptance for Filing of Triferic New Drug Application 58
May 22, 2014: Keryx Receives Notification of PDUFA Date Extension for Zerenex 58

Appendix 59

Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products under Development for Iron Deficiency Anemia, H1 2015 7
Number of Products under Development for Iron Deficiency Anemia Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Iron Deficiency Anemia Pipeline by Panion & Bf Biotech Inc, H1 2015 16
Iron Deficiency Anemia Pipeline by Rockwell Medical, Inc., H1 2015 17
Iron Deficiency Anemia Pipeline by Vifor Pharma AG, H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Route of Administration, H1 2015 21
Number of Products by Stage and Molecule Type, H1 2015 23
Iron Deficiency Anemia Therapeutics Recent Pipeline Updates, H1 2015 35
Iron Deficiency Anemia Dormant Projects, H1 2015 49

List of Figures
Number of Products under Development for Iron Deficiency Anemia, H1 2015 7
Number of Products under Development for Iron Deficiency Anemia Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Routes of Administration, H1 2015 20
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 21
Number of Products by Top 10 Molecule Types, H1 2015 22
Number of Products by Stage and Top 10 Molecule Types, H1 2015 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *